PARKINSONS & PARKINSONISM-LSVT EVIDENCE

From NeuroRehab.wiki

Revision as of 03:41, 21 February 2023 by Dr Appukutty Manickam (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

SUMMARY

1. Increased vocal sound pressure levels from 8 to 13 dB across a variety of speech tasks.

2. Follow-up studies found that these sound levels were maintained above pre-treatment levels up to 1 year.

3. Other changes included increased duration of sustained vowel phonation, maximum range of fundamental frequency, and fundamental frequency variability during speech, reductions in the rate of speech.

4. Increased subglottic air pressure and improved maximum flow declination rate.

5. Improved true vocal fold adduction.

6. Preliminary data from laryngeal EMG showed improved thyroarytenoid muscle activity, thereby improving vocal loudness and quality.

Ref: Fox, Cynthia M., et al. "Current Perspectives on the Lee Silverman Voice Treatment (LSVT) for Individuals With Idiopathic Parkinson Disease." American Journal of Speech-Language Pathology, vol. 11, no. 2, May 2002, pp. 111-123., doi:10.1044/1058-0360(2002/012).


Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].